Serrated polyposis (hyperplastic polyposis) is characterized by multiple polyps with serrated architecture in the colorectum. Although patients with serrated polyposis are known to be at increased risk of colorectal cancer (CRC) and possibly extracolonic cancers, cancer risk for their relatives has not been widely explored. The aim of this study was to estimate the risks of CRC and extracolonic cancers for relatives of patients with serrated polyposis.
INTRODUCTION
Serrated polyposis, also known as hyperplastic polyposis, is a condition characterized by the presence of multiple epithelial polyps with serrated architecture in the colon and rectum ( 1 ) . Patients with serrated polyposis are among the most diffi cult patient groups encountered in genetics clinics as they have no apparent causative germline mutation, and the phenotype is highly variable with a vast array of polyp numbers, sizes, and histological subtypes ( 2 ) . Approximately 1 in 3,000 individuals at age 55 -64 years in the United Kingdom are thought to have serrated polyposis, and 50 % of them have been identifi ed to additionally have at least one conventional colorectal adenoma ( 3 ) . Th ese patients are at increased risk of early-onset colorectal cancer (CRC) ( 4 -10 ) and possibly extracolonic cancers ( 11 ) .
As refl ected in the recently modifi ed WHO clinical criteria ( 1 ), serrated polyposis likely encompasses a group of diseases, rather than a single disease, or a continuum, which is infl uenced by a variety of genetic and environmental modifi ers. Although serrated polyposis has the hallmarks of a genetic disease (young onset, multiplicity of polyps and cancers, and restricted ethnicity), an underlying genetic alteration has yet to be found. A family history of CRC has been reported for 33 -59 % of serrated polyposis patients ( 6, 12, 13 ) , although other reports have suggested that this was a rare situation ( 14, 15 ) . Boparai et al. ( 16 ) estimated that the fi rst-degree relatives of serrated polyposis patients had fi ve times the incidence of CRC (standardized incidence ratio (SIR) 5.4; 95 % confi dence interval (CI) 3.7 -7.8), which is a greater increased risk than for relatives of CRC cases, and 39 times the incidence of serrated polyposis (SIR 39; 95 % CI 13 -121) compared with the general population. Inherited CRC predisposition syndromes are, however, seldom confi ned to the colorectum. Th is can be seen in the autosomal dominantly inherited Lynch syndrome ( 17 ) and familial adenomatous polyposis ( 18 ) where increased risks of various extracolonic cancers are well reported.
Th e specifi c risk of extracolonic cancers for relatives of patients with serrated polyposis has not been reported, although extracolonic cancers have been noted in several previous publications ( 11, 19, 20 ) . In this study, we have estimated the risks of CRC and extracolonic cancers for the fi rst-and second-degree relatives of patients with serrated polyposis.
METHODS

Study Sample
We studied the fi rst-and second-degree relatives of patients with multiple serrated polyps (>5) outside the rectum without a personal history of any cancer before diagnosis of serrated polyposis (index cases). Index cases were recruited between 2000 and 2010 from genetics clinics in Australia, New Zealand, Canada, and the USA regardless of a family history of polyps or cancer, and represented the initial presentation in each family. All index cases diagnosed owing to family screening, or carrying pathogenic mutations in mismatch repair genes or the MUTYH gene were excluded from the study. All index cases were referred to genetics clinics for hyperplastic polyposis (regardless of whether they had a personal or family history of CRC). Index cases were recruited by the Australasian Colorectal Cancer Family Registry ( 21 ) , and the Genetics of Serrated Neoplasia study ( http://www.qimr.edu. au/page/GSN/ ) to which Ohio State University Medical Center (USA), Familial Gastrointestinal Cancer Registry (Ontario, Canada), Memorial University of Newfoundland (Canada), the Genetics Clinics of Australia, and the New Zealand Familial Gastrointestinal Cancer Registry have contributed ( 5, 12 ) .
Attempts were made to contact (via the index case) and interview the relatives of index cases identifi ed via the Australasian Colorectal Cancer Family Registry. Written informed consents were obtained from all the participants to take part in the research and the study protocols were approved by local institutional research ethics review boards, as well as the Human Research Ethics Committee of the Queensland Institute of Medical Research (Protocols P628 and P912).
Data Collection
Information on demographics, personal characteristics, personal and family history of polyps, cancer, colonoscopic surveillance, and surgery were obtained from index cases (and all participating relatives in some clinics) at the time of recruitment. Reported cancer diagnoses and age at diagnosis were confi rmed, where possible, using pathology reports or medical records. Pathology review of polyps was undertaken by a specialist gastrointestinal pathologist (CR or NIW) and information regarding the number, size, distribution, gross morphology, and histology of polyps was derived from the colonoscopy and histopathology reports. Th e total numbers of each polyp type were estimated during colonoscopy or from the surgical specimen if a colectomy was performed. Permission to access tumor tissue was obtained from participants.
To reduce the possibility of unintentionally including cases of metastatic cancer; cancers of lung, liver, bone, and brain were only included if no other cancer was reported at or before the age of diagnosis.
Defi nitions
Serrated polyps were defi ned as any polyp with serrated crypt architecture ( 22 ) , which includes both non-dysplastic polyps (hyperplastic polyp and sessile serrated adenoma / polyp) and dysplastic polyps (traditional serrated adenoma and sessile serrated adenoma / polyp with cytological dysplasia). Where polyp count was known, polyposis was categorized into two groups: those fulfi lling WHO criterion-3 ( > 20 polyps throughout the colon) and those fulfi lling WHO criterion-1 ( > 5 serrated polyps beyond the rectosigmoid with two exceeding 10 mm in diameter) ( 1 ) . Depending on polyp count, where known, polyposis was also defi ned as moderate (5 -79 polyps) or dense ( ≥ 80 polyps).
Statistical Analysis
Cancer-specifi c SIRs were calculated by dividing the observed numbers of cancers for the fi rst-and second-degree relatives of patients with serrated polyposis by the expected numbers. Th e expected numbers of cancers were calculated by multiplying the age-, sex-, and country-specifi c incidence for the general population with the corresponding observation time (person-years from birth) of the relatives. Age-and sex-specifi c cancer incidences in 1988 -1992 ( 23 ) . Th e period of 1988 -1992 was selected for analysis because it was the closest available dataset to the mean calendar year of cancer diagnoses in the sample. Th e Jackknife method was used to estimate 95 % CIs by allowing for any correlation of risk between relatives from the same family ( 24 ) . Observation time for each subject started at birth and ended at the age at fi rst diagnosis of cancer or last contact or death, whichever occurred fi rst. For CRC, we censored each subject at the age of polypectomy except when it occurred within a year of the diagnosis of CRC ( n = 1). All index cases were excluded from the analysis.
Missing ages were estimated by the use of a defi ned protocol. For relatives with missing ages at cancer diagnoses (31 % of all cases), we assumed the age of diagnosis to be 1 year before the last known age or, if last known age was not available, the median age at diagnosis of the specifi c cancer for the general population. Th e cancer-specifi c median age for each sex was obtained from the Queensland Cancer Registry for relatives from Australia and New Zealand ( 25 ) , and Surveillance, Epidemiology and End Results Cancer Statistics Review (1996 -2000) for relatives from Canada and the USA ( 26 ) . For unaff ected relatives with missing ages at last contact (229 fi rst-and 507 second-degree relatives), if an exact age was not known but an age range was provided, age was estimated as the midpoint of that range. In the absence of any age information, it was assumed that both parents of a common child were born in the same year, that a parent was aged 25 years at birth of a fi rst child, and that there were 2 years between the births of children.
Th e SIRs of CRC for relatives were estimated stratifi ed by the characteristics of polyps diagnosed in the index case: age at diagnosis ( < 50 and ≥ 50 years), nature of polyps (with or without adenocarcinoma), polyp distribution (proximal colon and pancolonic), and density of polyps (5 -79 polyps and ≥ 80 polyps). All reported statistical tests were two sided and P < 0.05 was considered statistically signifi cant. All these statistical analyses were done using Stata 11.0 ( 27 ) .
Estimated cumulative risks (penetrance) of cancers to age 70 years and their 95 % CIs for each sex were calculated by summing over sex-specifi c incidences incidence i at age i multiplied by the estimated SIR, based on the population incidences of Australia, using the formula:
SIRincidence i i age
RESULTS
A total of 120 cases were recruited regardless of a family history of colorectal polyps or cancer. Of these, 20 cases were excluded because 14 were diagnosed owing to family screening, 5 carried mismatch repair gene mutations, and 1 carried a biallelic MUTYH mutation. Th e remaining 100 cases (33 were recruited from Australia, 41 from New Zealand, 6 from Canada, and 20 from the USA) had 609 fi rst-degree relatives (316 females) and 1,030 second-degree relatives (488 females) contributing data for this analysis ( Table 1 ) .
Of the 100 index cases (63 % female), minimum polyp counts were available from 66 (66 % ) of whom all but 7 met WHO criterion-3 ( > 20 serrated polyps throughout the colon). Of the 84 index cases whose location of polyps was known, 81 (96 % ) had pancolonic polyposis and 3 (4 % ) had polyposis concentrated in the proximal colon. Th irty-one of the 100 index cases had CRC (31 % ) and 17 of these (55 % ) were located in the proximal colon. Th ree proximal CRCs were multiple synchronous cancers. Average age at diagnosis was 48 years (standard deviation 15) and average minimal polyp number observed in index cases was 45 (standard deviation 32; Table 2 ). Sessile serrated adenomas were described in 32 / 64 females (50 % ) and 11 / 36 males (31 % ). Details of each case are available in Supplementary Table S1 online.
We observed a total of 102 CRCs in the fi rst-and second-degree relatives combined (SIR 2.25, 95 % CI 1.75 -2.93; P < 0.001), with 54 in fi rst-degree relatives (SIR 5.16, 95 % CI 3.70 -7.30; P < 0.001) and 48 in second-degree relatives (SIR 1.38, 95 % CI 1.01 -1.91; P = 0.04; Table 3 ). Th e risk of CRC for relatives was greater when the index case was diagnosed at age < 50 years compared with when the index case was diagnosed at age 50 years or older, but this did not reach statistical signifi cance ( P = 0.07). Th ere was no statistical evidence for diff erence in risks of CRC for relatives when numbers of polyps diagnosed in the index case were considered ( Table 4 ) . Th e median age at which CRC developed in fi rst-degree relatives was 55 years and in second-degree relatives was 66 years. Th e average age at diagnosis of CRC in either the fi rst-or second-degree relatives of patients with serrated polyposis diagnosed under and over the age of 50 years was not signifi cantly diff erent ( P = 0.97).
A total of 11 pancreatic cancers were observed in this study cohort in which 6 cases were in fi rst-degree relatives (SIR 3.64, 95 % CI 1.70 -9.21; P = 0.003). We observed no evidence of an increased risk for cancer of the stomach, brain, prostate, or female breast cancer. Cancers of other organs were observed in the cohort as follows: kidney ( n = 3), urinary bladder ( n = 5), leukemia ( n = 5), lymphoma ( n = 5), myeloma ( n = 2), bone ( n = 3), thyroid ( n = 2), oesophagus ( n = 5), liver ( n = 5), biliary tract ( n = 1), endometrium ( n = 3), ovary ( n = 4), cervix ( n = 4), and testis ( n = 1). Table 5 shows the estimated cancer-specifi c cumulative risk (penetrance) for fi rst-and second-degree relatives of patients with serrated polyposis. Th e estimated cumulative risks at age 70 years for the fi rst-degree relatives were: for CRC, 15 % (95 % CI 11 -21 % ) for men and 12 % (95 % CI 8 -16 % ) for women and for pancreatic cancer, 2 % (95 % CI 1 -6 % ) for men and 1.5 % (95 % CI 0.7 -4 % ) for women. When the index case was diagnosed at age < 50 years, the cumulative risk of CRC for fi rst-degree relatives was 24 % (95 % CI 15 -39 % ) for men and 19 % (95 % CI 11 -30 % ) for women. When the index case was diagnosed at age 50 years, the cumulative risk of CRC for fi rst-degree relatives was 13 % (95 % CI 9 -20 % ) for men and 10 % (95 % CI 7 -15 % ) for women.
DISCUSSION
First-and second-degree relatives of patients with serrated polyposis had a signifi cantly increased risk of developing CRC. In addition, fi rst-degree relatives demonstrated a signifi cantly increased risk of pancreatic cancer. Together these fi ndings support an inherited component for serrated polyposis. Th ough increased risks for fi rst-degree relatives could be due to shared environment, the observation that the CRC risk extended to second-degree relatives, and that relatives were also at increased risk for extracolonic cancers, increases the likelihood of a genetic etiology for serrated polyposis ( 28 ) . Our estimate of CRC risk for fi rst-degree relatives did not diff er signifi cantly from the relative risk estimated by Boparai et al. ( 16 ) 
Extracolonic cancers in relatives of a BRAF -mutated CRC proband (implying origin in a serrated polyp) were first described in a Swedish study of familial CRC in 2006 ( 20 ) , and further extracolonic associations were seen in a Canadian study ( 29 ) . A single anecdotal report ( 19 ) and a clinical description ( 11 ) reported occurrence of extracolonic cancers in serrated polyposis patients and their relatives. However, until our study, the magnitude of extracolonic cancer risk for relatives had not been estimated. A range of extracolonic cancers were observed in the study cohort but the cancer-specific numbers were too low to determine with any degree of certainty whether they occurred more often than expected. Common cancers such as those of the breast, lung, and prostate were not increased above what would be expected in the population. An apparent decreased risk for lung cancer was observed in second-degree relatives. We have no explanation for this association; however, it may be a consequence of our analysis excluding any second cancers within 1 year of the first cancer diagnosis, which was done to minimise inclusion of metastatic disease.
We observed a signifi cantly increased risk of pancreatic cancer for fi rst-degree relatives of patients with serrated polyposis, which is a novel fi nding. No cases of pancreatic cancer were seen in the serrated polyposis cases themselves, although given the young average age at diagnosis of polyposis (48 years), this is not unexpected. Pancreatic cancer occurs in familial cancer syndromes such as Peutz -Jeghers syndrome ( 30 ) and familial atypical multiple mole melanoma syndrome ( 31 ) where its risk ranges from 9-to132-fold that of the population. It also occurs in familial pancreatitis, with a relative risk of 50 -80-fold, and in families with mutations in BRCA2 and its binding partner PALB2 , where the risk varies from 3.5-to 10-fold that of the population ( 32 ). Our estimate for pancreatic cancer risk in serrated polyposis at 3.64 is commensurate with the lower estimates for BRCA2 families. In population terms, the pancreas is less likely to develop a malignancy than any other organ in the gastrointestinal tract, with the exception of the small intestine ( 32 ). Pancreatic cancer is highly age dependent, and occurs in 
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the population around 70 years of age ( 33, 34 ) . Th e median age at diagnosis for pancreatic cancer in our study was 73 years, not indicative of an early-age of onset. Rather, the increased frequency is suggestive of an enhanced response to risk factors such as smoking, obesity, and diabetes ( 34 ), factors which are also associated with the development of serrated polyps ( 35 ) . Pancreatic cancer is diffi cult to prevent and there are currently no robust screening tests for early detection. Endoscopic ultrasound has been trialed in very high-risk families and has shown some promise in the detection of early precursor lesions in asymptomatic individuals ( 36 ) .
Biological explanations for the association between serrated polyposis and extracolonic cancers are not known; however, our fi ndings support the hypothesis that this condition represents an inherited cancer predisposition in which the phenotype is most strongly expressed in the colorectum. It is also possible that environmental triggers may be interacting with the genetic predisposition to produce both colonic and extracolonic cancers. Finally, more than one condition may be segregating in these families. Jarrar et al. ( 19 ) reported that 7 of 651 families who met the criteria of Amsterdam I, Amsterdam II, Amsterdam-like, or familial colorectal cancer, had a high prevalence of serrated The summation of these numbers may not be the same with the total of CRC observed in fi rst-and second-degree relatives because of missing data on polyp characteristics (age of onset, location, and minimum polyp counts).
rated polyposis identifi ed in a clinical setting. As all index cases were recruited from genetics clinics, this raises the possibility that relatives of symptomatic patients may represent a more aggressive phenotype associated with a higher " familial risk profi le " compared with other asymptomatic patients. However, symptoms such as abdominal pain or change in bowel habit, which fi rst brought the index patients to their primary care clinician, are also very common outside the setting of serrated polyposis, and may have had nothing to do with their serrated polyposis condition ( 41, 42 ) . Th erefore, it is not possible to state at this time that an aggressive phenotype should be inferred. A further limitation of the study is that it is not possible to know whether an endoscopist referred the patient to a genetics clinic because of polyp burden or because of family history. As the family history data used in this study were determined using genetics clinic pedigree records, we do not know the extent of family history recorded by the endoscopists. However, it has been observed that even in high-risk patients diagnosed at age < 50 years, family history was not noted in 49 -83 % of cases ( 43, 44 ) . Our fi ndings suggest that relatives of patients with serrated polyposis could benefi t from appropriate colonoscopic surveillance. Current practice for fi rst-degree relatives is usually fi ve-yearly colonoscopy from the age of 40 -50 years or from an age 5 years younger than the age at which serrated polyposis was diagnosed in the family. Th e median age at which CRC was diagnosed in fi rst-degree relatives in our study (55 years old) supports these guidelines for surveillance. Further independent studies are required to confi rm the risks of extracolonic cancers for relatives of patients with serrated polyposis. Also, given the arbitrary nature of the current criteria for the identifi cation of serrated polyposis ( 1 ) and the initial observation of extracolonic cancers in relatives of index cases whose CRC arose from a serrated polyp ( 20 ) , the implications of this fi nding may be applicable beyond the stringent criteria for diagnosis of serrated polyposis, identifying some families with both CRC and pancreatic cancer (in which Lynch syndrome is excluded) as having a serrated neoplasia predisposition.
Th is large, international study has observed that relatives of serrated polyposis patients are at signifi cantly increased risks of colorectal and pancreatic cancer. Th ese fi ndings add to the accumulating evidence that serrated polyposis has an inherited component, while also highlighting the need for surveillance in relatives of patients with serrated polyposis.
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polyps. One of the scenarios raised in that report was a co-occurrence of two cancer pathways: Lynch syndrome and serrated polyposis. However, our fi ndings suggest that the cancers observed in relatives of serrated polyposis patients are unlikely to be due to co-occurring Lynch syndrome mutations as index cases with a mismatch repair gene mutation were excluded from the study.
Serrated polyposis as currently defi ned is likely to comprise a heterogeneous group of conditions. Th e pattern of inheritance in at least some serrated polyposis patients may be consistent with a recessive mode ( 37 ), analagous to MUTYH -associated polyposis caused by germline mutations in the MUTYH gene. Increased risks of cancer for relatives of patients with MUTYH -associated polyposis have been found for CRC, duodenal, ovary, bladder, and skin cancer for biallelic mutation carriers ( 38 ) . Moreover, an increased risk of CRC, gastric, and endometrial cancer has been reported for monoallelic mutation carriers ( 39 ) . Until a genetic cause is identifi ed for serrated polyposis, studies will continue to be based on a clinical defi nition.
Th e strengths of this study are that (i) it was based, to our knowledge, on the largest sample to date of relatives of index patients with serrated polyposis; (ii) it is the fi rst study to quantify the risks of extracolonic cancers for relatives of patients with serrated polyposis; (iii) index cases were not ascertained because of a previous family history of polyps or cancer and, therefore, the estimates from this study are less likely to be infl ated owing to ascertainment bias ( 40 ) ; and (iv) we accounted for familial correlation in the risk of cancer to derive appropriate measure of estimate imprecision.
Our study has several limitations, including the presence of unverifi ed cancers, unaccounted for time and geographic variation. Th ese might increase the imprecision of estimates more than indicated by the reported CIs. Estimates from this study should be generalizable to relatives of symptomatic patients with ser- 
